48,830
edits
Line 42: | Line 42: | ||
**Central nuclei +/- small/indistinct nucleoli. | **Central nuclei +/- small/indistinct nucleoli. | ||
**Surrounded by a prominent lymphoid component - '''key feature'''. | **Surrounded by a prominent lymphoid component - '''key feature'''. | ||
*+/-[[Urothelial carcinoma in situ]]. | |||
DDx: | DDx: | ||
Line 60: | Line 61: | ||
</ref> | </ref> | ||
*[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0003/ LELC of the urinary bladder - high mag. (nih.gov)].<ref name=pmid19847088/> | *[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2881438/figure/F0003/ LELC of the urinary bladder - high mag. (nih.gov)].<ref name=pmid19847088/> | ||
==IHC== | |||
Features:<ref name=pmid21383609/> | |||
*p53 +ve/-ve. | |||
*CK20 -ve. | |||
*TTF-1 -ve. | |||
*CD30 -ve. | |||
*CK34betaE12 +ve (+ve in 75% of cases). | |||
*CK7 +ve/-ve (+ve in ~60% of cases). | |||
*p63 +ve/-ve (+ve in ~50% of cases). | |||
==See also== | ==See also== |
edits